A phase 1 clinical trial evaluating MAGE-A4/MAGE-A8-targeted T cell engager therapy has been subject to an author correction published in Nature Medicine, highlighting the importance of data accuracy in oncology research. The trial enrolled patients with difficult-to-treat solid tumours that had recurred or become resistant to prior therapeutic interventions.
MAGE-A4 and MAGE-A8 are tumour-associated antigens expressed across several cancer types, making them attractive targets for immunotherapeutic intervention. The TCR-based bispecific engager represents an innovative cell therapy strategy designed to mobilise patient immune systems against these malignancies.
The published correction emphasises the rigorous standards applied to clinical trial reporting and reinforces confidence in the scientific validation of emerging cancer therapies. Read the full article on GMJ Newsroom.
Was this article helpful?
